Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
From dysmotility to virulent pathogens: implications of opioid use in the ICU
Chapple, LA; Deane, A
(2018), Curr. Opin. Crit. Care, 118-123
Energy-Dense versus Routine Enteral Nutrition in the Critically Ill
Chapman, M; Peake, SL; Bellomo, R; Davies, A; Deane, A; Horowitz, M; Hurford, S; Lange, K; Little, L; Mackle, D; O'Connor, S; Presneill, J; Ridley, E; Williams, P; Young, P
(2018), N. Engl. J. Med., 1823-1834
Patient characteristics, incidence, technique, outcomes and early prediction of tracheostomy in the state of Victoria, Australia
Casamento, A; Bailey, M; Robbins, R; Pilcher, D; Warrillow, S; Ghosh, A; Bellomo, R
(2018), J. Crit. Care, 278-284
Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis of the LUNG SAFE database
Boyle, AJ; Madotto, F; Laffey, JG; Bellani, G; Pham, T; Pesenti, A; Thompson, BT; O'Kane, CM; Deane, AM; McAuley, DF
(2018), Crit. Care
Early repeat computed tomographic imaging in transferred trauma and neurosurgical patients: Incidence, indications and impact
Blazak, P; Hacking, C; Presneill, J; Reade, M
(2018), J. Med. Imag. Radiat. Oncol., 480-486
Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing
Sim, SA; Leung, VKY; Ritchie, D; Slavin, MA; Sullivan, SG; Teh, BW
(2018), Biol. Blood Marrow Transplant., 1490-1496
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma
Gherardin, NA; Loh, L; Admojo, L; Davenport, AJ; Richardson, K; Rogers, A; Darcy, PK; Jenkins, MR; Prince, HM; Harrison, SJ; Quach, H; Fairlie, DP; Kedzierska, K; McCluskey, J; Uldrich, AP; Neeson, PJ; Ritchie, DS; Godfrey, DI
(2018), Sci Rep
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients
Willcox, A; Wong, E; Nath, C; Janson, B; Harrison, SJ; Hoyt, R; Bajel, A; Shaw, P; Ritchie, D; Grigg, A
(2018), Ann. Hematol., 2509-2518
Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34(+) Yields Are Less
Stroncek, DF; Shaw, BE; Logan, BR; Kiefer, DM; Savani, BN; Anderlini, P; Bredeson, CN; Hematti, P; Ganguly, S; Diaz, MA; Abdel-Azim, H; Ahmed, I; Maharaj, D; Seftel, M; Beitinjaneh, A; Seo, S; Yared, JA; Halter, J; O'Donnell, PV; Hale, GA; DeFilipp, Z; Lazarus, H; Liesveld, JL; Zhou, Z; Munshi, P; Olsson, RF; Kasow, KA; Szer, J; Switzer, GE; Chitphakdithai, P; Shah, N; Confer, DL; Pulsipher, MA
(2018), Biol. Blood Marrow Transplant., 175-184
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D; Kelly, GL; Lessene, G; Wei, AH; Roberts, AW; Strasser, A
(2018), Cancer Cell, 879-891
Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia
Sharpe, C; Davis, J; Mason, K; Tam, C; Ritchie, D; Koldej, R
(2018), J. Immunol. Methods, 97-104
Mechanisms of Action and Clinical Development of Elotuzumab
Ritchie, D; Colonna, M
(2018), CTS-Clin. Transl. Sci., 261-266
DOI: 10.1111/cts.12532
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy
Mastaglio, S; Wong, E; Perera, T; Ripley, J; Blombery, P; Smyth, MJ; Koldej, R; Ritchie, D
(2018), Blood Adv., 335-346
P2X7 polymorphisms and stem cell mobilisation
Koldej, R; Collins, J; Ritchie, D
(2018), Leukemia, 2724-2726
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
Davenport, AJ; Cross, RS; Watson, KA; Liao, Y; Shi, W; Prince, HM; Beavis, PA; Trapani, JA; Kershaw, MH; Ritchie, DS; Darcy, PK; Neeson, PJ; Jenkins, MR
(2018), Proc. Natl. Acad. Sci. U. S. A., E2068-E2076
Recent advances and future challenges in Gaucher disease
Zimran, A; Szer, J
(2018), Blood Cells Mol. Dis., 9-13
Preface to the special issue on Gaucher disease 2017
Zimran, A; Szer, J
(2018), Blood Cells Mol. Dis., 1-2
Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease
Zimran, A; Revel-Vilk, S; Becker-Cohen, M; Chicco, G; Arbel, N; Rolfs, A; Szer, J
(2018), Am. J. Hematol., E246-E248
DOI: 10.1002/ajh.25205
Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
Zimran, A; Goldblatt, J; Szer, J
(2018), Blood Cells Mol. Dis., 14-16
Addressing Ethical and Procedural Principles for Unrelated Allogeneic Hematopoietic Progenitor Cell Donation in a Changing Medical Environment
van Walraven, SM; Egeland, T; Borri, V; Faveri, GND; Rall, G; Szer, J
(2018), Biol. Blood Marrow Transplant., 887-894
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Tiong, IS; Reynolds, J; Bradstock, KF; Seymour, JF; Wei, AH
(2018), Blood Cancer J.
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, TC; Nguyen, NY; Moujalled, DM; Segal, D; Pomilio, G; Rijal, S; Jabbour, A; Cummins, K; Lackovic, K; Blombery, P; Thompson, E; Ekert, PG; Lessene, G; Glaser, SP; Huang, DCS; Roberts, AW; Guthridge, MA; Wei, AH
(2018), Leukemia, 303-312
DOI: 10.1038/leu.2017.243
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia
Tam, CS; LeBlond, V; Novotny, W; Owen, RG; Tedeschi, A; Atwal, S; Cohen, A; Huang, J; Buske, C
(2018), Future Oncol., 2229-2237
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, CS; Anderson, MA; Pott, C; Agarwal, R; Handunnetti, S; Hicks, RJ; Burbury, K; Turner, G; Di Iulio, J; Bressel, M; Westerman, D; Lade, S; Dreyling, M; Dawson, SJ; Dawson, MA; Seymour, JF; Roberts, AW
(2018), N. Engl. J. Med., 1211-1223
Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Stathis, A; Iasonos, A; Seymour, JF; Thieblemont, C; Ribrag, V; Zucca, E; Younes, A
(2018), Clin. Cancer Res., 2993-2998
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, JF; Kipps, TJ; Eichhorst, B; Hillmen, P; D'Rozario, J; Assouline, S; Owen, C; Gerecitano, J; Robak, T; De la Serna, J; Jaeger, U; Cartron, G; Montillo, M; Humerickhouse, R; Punnoose, EA; Li, Y; Boyer, M; Humphrey, K; Mobasher, M; Kater, AP
(2018), N. Engl. J. Med., 1107-1120
Selected state of the art research in internal medicine, 2017
Scott, I; McGavigan, A; Ferson, M; Woolley, I; Burt, MG; Russell, A; Bridgman, P; Ting, J; Blacker, D; Bonomo, Y; Martin, J; Szer, J
(2018), Intern. Med. J., 619-623
DOI: 10.1111/imj.13820
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
Sanders, MA; Chew, E; Flensburg, C; Zeilemaker, A; Miller, SE; al Hinai, AS; Bajel, A; Luiken, B; Rijken, M; McIennan, T; Hoogenboezem, RM; Kavelaars, FG; Frohling, S; Blewitt, ME; Bindels, EM; Alexander, WS; Lowenberg, B; Roberts, AW; Valk, PJM; Majewski, IJ
(2018), Blood, 1526-1534
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
Roth, A; Rottinghaus, ST; Hill, A; Bachman, ES; Kim, JS; Schrezenmeier, H; Terriou, L; Urbano-Ispizua, A; Wells, RA; Jang, JH; Kulasekararaj, AG; Szer, J; Aguzzi, R; Damokosh, AI; Shafner, L; Lee, JW
(2018), Blood Adv., 2176-2185